tiprankstipranks
Trending News
More News >
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
US Market

ATAI Life Sciences (ATAI) Stock Forecast & Price Target

Compare
1,229 Followers
See the Price Targets and Ratings of:

ATAI Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
ATAI
Life Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ATAI Stock 12 Month Forecast

Average Price Target

$8.00
▲(246.32%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $8.00 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 246.32% change from the last price of $2.31.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","9":"$9","12":"$12"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3,6,9,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Sep<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,2.203076923076923,2.936153846153846,3.6692307692307695,4.4023076923076925,5.135384615384615,5.868461538461538,6.601538461538461,7.334615384615384,8.067692307692308,8.80076923076923,9.533846153846154,10.266923076923078,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,1.9723076923076923,2.474615384615385,2.976923076923077,3.479230769230769,3.9815384615384612,4.483846153846154,4.986153846153846,5.4884615384615385,5.990769230769231,6.493076923076923,6.995384615384616,7.497692307692308,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.47,1.7415384615384615,2.013076923076923,2.2846153846153845,2.556153846153846,2.827692307692308,3.0992307692307692,3.370769230769231,3.6423076923076927,3.913846153846154,4.185384615384615,4.456923076923077,4.728461538461539,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$11.00Average Price Target$8.00Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ATAI
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
-35.06%
Downside
Reiterated
05/16/25
ATAI Life Sciences' overall stock score reflects significant financial challenges, including persistent losses and negative cash flows. The recent technical indicators suggest some short-term positive momentum, but the company's negative valuation metrics and reliance on external funding are key concerns. The early repayment of the Hercules loan is a positive corporate event but does not significantly alter the overall financial outlook.
TD Cowen Analyst forecast on ATAI
Ritu BaralTD Cowen
TD Cowen
Buy
Reiterated
05/21/25
TD Cowen Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)
Jefferies Analyst forecast on ATAI
Andrew TsaiJefferies
Jefferies
$5
Buy
116.45%
Upside
Reiterated
05/20/25
ATAI Life Sciences: Promising Clinical Data and Strategic Investments Drive Buy Rating
H.C. Wainwright Analyst forecast on ATAI
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$10
Buy
332.90%
Upside
Reiterated
05/20/25
ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones
Maxim Group
$6
Buy
159.74%
Upside
Reiterated
05/15/25
ATAI Life Sciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
Canaccord Genuity Analyst forecast on ATAI
Sumant KulkarniCanaccord Genuity
Canaccord Genuity
$11
Buy
376.19%
Upside
Reiterated
05/14/25
ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts
Berenberg Bank Analyst forecast on ATAI
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
Buy
Initiated
04/03/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ATAI
TipRanks AITipRanks
Not Ranked
TipRanks
$1.5
Hold
-35.06%
Downside
Reiterated
05/16/25
ATAI Life Sciences' overall stock score reflects significant financial challenges, including persistent losses and negative cash flows. The recent technical indicators suggest some short-term positive momentum, but the company's negative valuation metrics and reliance on external funding are key concerns. The early repayment of the Hercules loan is a positive corporate event but does not significantly alter the overall financial outlook.
TD Cowen Analyst forecast on ATAI
Ritu BaralTD Cowen
TD Cowen
Buy
Reiterated
05/21/25
TD Cowen Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)
Jefferies Analyst forecast on ATAI
Andrew TsaiJefferies
Jefferies
$5
Buy
116.45%
Upside
Reiterated
05/20/25
ATAI Life Sciences: Promising Clinical Data and Strategic Investments Drive Buy Rating
H.C. Wainwright Analyst forecast on ATAI
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$10
Buy
332.90%
Upside
Reiterated
05/20/25
ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones
Maxim Group
$6
Buy
159.74%
Upside
Reiterated
05/15/25
ATAI Life Sciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
Canaccord Genuity Analyst forecast on ATAI
Sumant KulkarniCanaccord Genuity
Canaccord Genuity
$11
Buy
376.19%
Upside
Reiterated
05/14/25
ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts
Berenberg Bank Analyst forecast on ATAI
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
Buy
Initiated
04/03/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ATAI Life Sciences

1 Month
xxx
Success Rate
7/11 ratings generated profit
64%
Average Return
+1.69%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +1.69% per trade.
3 Months
xxx
Success Rate
6/11 ratings generated profit
55%
Average Return
+10.23%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +10.23% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
7/11 ratings generated profit
64%
Average Return
+21.01%
reiterated a buy rating 9 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +21.01% per trade.
2 Years
xxx
Success Rate
10/11 ratings generated profit
91%
Average Return
+39.17%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +39.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATAI Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
5
6
5
4
7
Buy
2
2
2
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
7
6
10
In the current month, ATAI has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATAI average Analyst price target in the past 3 months is 8.00.
Each month's total comprises the sum of three months' worth of ratings.

ATAI Financial Forecast

ATAI Earnings Forecast

Next quarter’s earnings estimate for ATAI is -$0.14 with a range of -$0.18 to -$0.09. The previous quarter’s EPS was -$0.15. ATAI beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.24% of the time in the same period. In the last calendar year ATAI has Outperformed its overall industry.
Next quarter’s earnings estimate for ATAI is -$0.14 with a range of -$0.18 to -$0.09. The previous quarter’s EPS was -$0.15. ATAI beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.24% of the time in the same period. In the last calendar year ATAI has Outperformed its overall industry.

ATAI Sales Forecast

Next quarter’s sales forecast for ATAI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $1.56M. ATAI beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year ATAI has Outperformed its overall industry.
Next quarter’s sales forecast for ATAI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $1.56M. ATAI beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year ATAI has Outperformed its overall industry.

ATAI Stock Forecast FAQ

What is ATAI’s average 12-month price target, according to analysts?
Based on analyst ratings, ATAI Life Sciences’s 12-month average price target is 8.00.
    What is ATAI’s upside potential, based on the analysts’ average price target?
    ATAI Life Sciences has 246.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ATAI a Buy, Sell or Hold?
          ATAI Life Sciences has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is ATAI Life Sciences’s price target?
            The average price target for ATAI Life Sciences is 8.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $11.00 ,the lowest forecast is $5.00. The average price target represents 246.32% Increase from the current price of $2.31.
              What do analysts say about ATAI Life Sciences?
              ATAI Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of ATAI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis